乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ADA

<乌鸦传媒>Two T1D Patients Achieve Insulin Independence After Stem Cell Transplants

These were patients with "really debilitating diabetes," says investigator

<乌鸦传媒>High-Dose Semaglutide Pill Just as Effective as Wegovy for Weight Loss

Another study showed two high doses were better at reducing HbA1c vs a 14-mg dose

<乌鸦传媒>Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial

Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease

<乌鸦传媒>Bempedoic Acid Gets 'Huge' Win for Primary Prevention in the Statin-Intolerant

More positive results in CLEAR Outcomes sub-analysis

<乌鸦传媒>Once-Weekly Insulin Icodec Bests Daily Insulin Options for Type 2 Diabetes

Superior to once-a-day insulin glargine U100 and degludec

<乌鸦传媒>Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial

Daily orforglipron also lowered HbA1c in type 2 diabetes

<乌鸦传媒>ADA 2022: Racial Residential Segregation, DKA During COVID, and More

Noteworthy research presented at the American Diabetes Association annual meeting

<乌鸦传媒>Don't Ignore Depression in Youth With Type 1 Diabetes

Depressive symptoms and history of suicide attempts linked with higher HbA1c

<乌鸦传媒>DIY Insulin Delivery System Safe, Effective for All Ages

Users spent more time in target glucose range than those on sensor augmented pump therapy

<乌鸦传媒>Concerning Trends in Vision Impairment for Adults With Diabetes?

Steady decreases in the prevalence of patients with eye problems may be over

<乌鸦传媒>T1D Patient Achieves Full Insulin Independence After Stem Cell Transplant

But clinical trial currently under FDA hold as dosing is discussed

<乌鸦传媒>Tirzepatide Reduced Albuminuria in T2D Patients With Heart Risk

Subanalysis of SURPASS-4 trial compared the GLP-1/GIP agonist against insulin glargine

<乌鸦传媒>Is Diabetes a Risk Factor for Long COVID? Possibly.

Mixed results in seven-study scoping review

<乌鸦传媒>Dulaglutide Improves HbA1c for Youth With Type 2 Diabetes

Safety profile consistent with that reported in adults

<乌鸦传媒>Tirzepatide Serves Up Major Weight-Loss Win in Patients With Obesity

SURMOUNT-1 trial tested GIP/GLP-1 receptor agonist in people without diabetes

<乌鸦传媒>Bariatric Surgery Cuts Cancer Incidence, Death Risk

Study looked at people with obesity who underwent two most popular procedures

<乌鸦传媒>CDC Study: Income-Related Inequalities Widening in Diabetes

Disparities differed by sex and age group

<乌鸦传媒>ADA 2021 Roundup: SoliMix Trial; Byetta for Teens; Driving in Hypoglycemia

Noteworthy research from the American Diabetes Association virtual meeting

<乌鸦传媒>Genetics, Socioeconomic Factors Each Tied to Diabetes and Obesity

People with highest risk genetics more than 15 times more likely to have T2D

<乌鸦传媒>Liraglutide and Insulin Come Out on Top for Glycemic Control in GRADE study

Head-to-head comparison could help individualize treatment

<乌鸦传媒>COVID-19 Pandemic Upped Anxiety in Adults, Kids With Diabetes

Providers should be screening patients on how COVID is affecting them, says researcher

<乌鸦传媒>Investigational GLP-1 RA Cuts Heart, Renal Risk in Vulnerable Diabetes Patients

Exendin-4-based drug succeeded in cardiovascular outcomes trial

<乌鸦传媒>180-Day Continuous Glucose Monitor Shows Promise in Adults With Diabetes

Implantable Eversense system demonstrates accuracy in prospective study

<乌鸦传媒>Hospitalization Rates for New-Onset Type 2 Diabetes in Kids Took Off During Pandemic

"COVID-19 disrupted our lives in more ways than we realize"

<乌鸦传媒>Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D

40-week trial compared tirzepatide head-to-head with injectable semaglutide

<乌鸦传媒>Ertugliflozin Tx: Safe for the Heart in Patients With T2D

Phase III VERTIS-CV trial meets primary endpoint of MACE non-inferiority

<乌鸦传媒>No Added CV Risk for Oral Semaglutide in T2D

Safety study buffs resume for oral GLP-1 receptor agonist

<乌鸦传媒>Urine Marker Predicts Kidney Benefit With Trulicity

Secondary AWARD-7 analysis finds subgroup getting the most renal protection

<乌鸦传媒>Dapagliflozin Boosts Renal Function in T2D

Secondary outcomes build on previously reported cardiovascular benefit from SGLT2 inhibitors

<乌鸦传媒>Another GLP-1 Agent Cuts Heart Risk in T2D

Dulaglutide added to the growing list of diabetes treatments to show added benefit

<乌鸦传媒>Novel Anti-CD3 Antibody Delays Progression to T1D

Single course of teplizumab slowed march to clinical type 1 diabetes in high-risk people

<乌鸦传媒>Expert Panel Defines CGM Time-in-Range Targets

Seventy percent of readings should stay between 70-180 mg/dL, according to recommendations

<乌鸦传媒>Vitamin D Flops for Diabetes Prevention

Highly anticipated trial finds no significant difference compared to placebo after nearly three years follow-up

<乌鸦传媒>SGLT-2 Inhibitors Tied to Lower All-Cause Mortality Risk

Head-to-head comparison with DPP-4 inhibitors also showed heart protection

<乌鸦传媒>'Artificial Pancreas' System Boosts In-Hospital T2D Control

Less time out of range, no increase in insulin or lows with fully-automated system

<乌鸦传媒>Early T2D Treatment in Youth Disappoints

Metformin, insulin didn't stop deterioration of beta-cells in adolescents with impaired glucose

<乌鸦传媒>TB Vaccine for T1D Study Stirs Controversy

Long-term data suggest BCG vaccine may alter immune attack

<乌鸦传媒>Intensive Treatment Doesn't Cost More

Therapy aimed at treating all organ targets extends life

<乌鸦传媒>Farxiga Lowers HbA1c in Type 1 Diabetes

Weight loss also accompanied better glycemic control

<乌鸦传媒>Eversense CGM Comes Out on Top for Accuracy in T1D

Dexcom G5 performed best in hypoglycemia

1